A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab

作者:Xu, Binghe; Ma, Fei; Ouyang, Quchang; Li, Wei; Jiang, Zefei; Tong, Zhongsheng; Liu, Yunjiang; Li, Huiping; Yu, Shiying; Feng, Jifeng; Wang, Shusen; Hu, Xichun; Zhu, Xiaoyu; Zou, Jianjun
来源:San Antonio Breast Cancer Symposium, San Antonio, TX, 2017-12-05 To 2017-12-09.